RxDoctor Payments Data

Stewart Polsky, MD

Urology · Mooresville, NCNPI 1881670537

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Bayer at 51.2% of the total. 2025 is the largest year on record at $2,799, 6.6 times the $424 reported in 2019.

$7,319in general payments, 2019–2025

Across 37 payments — averaging $197.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$4K
  • Avyxa Pharma, LLC$3K
  • Dendreon Pharmaceuticals LLC$164
  • Teleflex LLC$125
  • Boston Scientific$118
  • Astellas Pharma US Inc$70
  • plus $350 from 9 others
$157,363in research payments, 2019–2025

Across 80 payments — averaging $1967.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$100K
  • Astellas Pharma Global Development$40K
  • Pfizer$9K
  • Janssen Research & Development, LLC$8K

What the payments were for

  • Consulting fees$3,74051%
  • Speaking & faculty fees$2,05028%
  • Travel & lodging$4957%
  • Food & beverage$99814%
  • Education$360%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer4$3,750
Avyxa Pharma, LLC6$2,743
Dendreon Pharmaceuticals LLC4$164
Teleflex LLC2$125
Boston Scientific1$118
Astellas Pharma US Inc4$70
Amgen3$61
Pfizer5$59
Angiodynamics, Inc.1$57
Blue Earth Diagnostics1$50
Mckesson Medical-surgical, Inc.1$50
Johnson & Johnson2$26
Aytu Biopharma, Inc.1$18
Olympus America Inc.1$17
Avadel Specialty Pharmaceuticals, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,319 in reported general payments places this provider in the 75th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$459,805
Medicare patients
931
Services billed
10,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide19$266,337
XtandiEnzalutamide16$217,605
GemtesaVibegron144$144,358
MyrbetriqMirabegron83$65,223
OrgovyxRelugolix17$41,176
Abiraterone Acetate21$33,197
Silodosin215$16,940
Tamsulosin Hcl849$12,199
Mirabegron ErMirabegron19$11,622
Finasteride406$4,956
Testosterone Cypionate109$3,903
Solifenacin Succinate102$3,608
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst202$2,931
Estradiol38$2,837
Testosterone26$2,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$70$282,82899 claims
BayerNubeqa$3,750$266,33719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 434 urology providers in North Carolina.

Other urology in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →